← FDA DRUG APPROVALS

FDA ANDA · ANDA209532

GEFITINIB

Sponsor: APOTEX

APPLICATION
ANDA209532
TYPE
ANDA
ORIGINAL APPROVAL
2022-09-23
LATEST ACTION
2022-09-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

GEFITINIBDiscontinued
GEFITINIB 250MG · TABLET · ORAL

Approval history

2022-09-23UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →